



## CytImmune Sciences Inc.

### *A Revolutionary New Concept for Treating Cancer*

**A Convertible Promissory Note issued at a 50% discount to the ASX IPO price, raising up to US\$ 2 million to:**

- **Prepare the Company's lead nanomedicine to enter a Phase II Clinical Trial in Pancreatic Cancer patients**
- **Bridge to an IPO on the ASX in 2018**
- ❖ CytImmune Sciences Inc. is a US biopharma company that has developed a family of nanomedicine drugs, which destroy blood vessels in solid tumours (up to 85% of all cancers)
- ❖ CytImmune has approval from the US Food and Drug Administration (**FDA**) to commence Phase II clinical studies. CytImmune will test CYT-6091 in Pancreatic Cancer patients
- ❖ CYT-6091 successfully completed human Phase 1 Safety studies
- ❖ CytImmune shall apply to the FDA for CYT-6091 targeting Pancreatic Cancer to be classified as an Orphan Drug, and upon the successful completion of the Phase II study apply for Breakthrough designation and Fast Track status. Successful entrants into accelerated approval programs with the FDA, European Medicine Agency (EMA) and the Therapeutic Goods Administration (TGA), typically have years and millions of dollars shaved off development
- ❖ CytImmune's lead drug, CTY-6091, is a gold bound tumour necrosis factor (TNF $\alpha$ ), which breaks apart blood vessels and enables chemotherapeutics to penetrate and kill cancer cells
- ❖ Perforating tumour blood vessels is significant, because the high-pressure level caused by fluid leakiness is a major reason for the reduction of the effectiveness of chemotherapeutics. Many prescribed cancer drugs experience difficulty penetrating tumours due to the high-pressure gradient, as the fluid pressure inside solid tumours can be up to 40 times greater than in normal tissue
- ❖ CYT-6091's action of perforating tumour blood vessels and reducing tumour pressure may make existing cancer therapies safer and more effective, by allowing for the increased concentration of cancer drugs into a tumour
- ❖ Laboratory studies of CYT-6091 pre-treatment of mice engineered to spontaneously develop Pancreatic Cancer resulted in 100% survival after 42 days when treated with chemotherapy, compared to 50% treated with chemotherapy alone and 0% untreated. Additional studies corroborated the advantages of CYT-6091, showing approx. 600% more chemotherapeutic concentrated in a tumour of CYT-6091 pre-treated mice compared to these mice treated with a chemotherapeutic alone
- ❖ This round is a limited offer to Corp Act (2001) s708 investors and professional investors as defined in the jurisdictions they reside.

**Dr Saliba Sassine**  
National Chairman  
+61 412 533 966  
saliba.sassine@bluemountcapital.com

**Kelvin Templeton**  
Regional Director MENA  
+61 407 179 530  
kelvin.templeton@bluemountcapital.com

**Michael Shaw**  
Managing Director  
+61 466 999 115  
michael.shaw@bluemountcapital.com

**Dr Mona Chung**  
Regional Director – China & Asia  
+61 414 271 678  
mona.chung@bluemountcapital.com

BlueMount Capital (Vic) Pty Ltd ACN 618 908 348  
Authorised Representative for AFSL 230680  
Level 11 - 461 Bourke Street Victoria 3000 Australia  
Website [www.bluemountcapital.com](http://www.bluemountcapital.com)



**CorporateINTL**  
GLOBAL AWARDS  
WINNER 2017

**PLEASE READ THE FOLLOWING INVESTOR WARNING:**

- (i) investment in new business carries high risks. It is highly speculative and before investing in any project about which information is given, prospective investors are strongly advised to take appropriate professional advice;
- (ii) the information prepared in this publication has been prepared by or on behalf of the person who is proposing to issue the securities and BlueMount Capital (VIC) Pty Ltd has not undertaken an independent review of the information contained in this publication;
- (iii) the information contained in this publication about the proposed business opportunity and the securities is not intended to be the only information on which the investment decision is made and is not a substitute for a prospectus or any other notice that may be required under the Corporations Law, as this law may apply to the investment. Detailed information may be needed to make an investment decision, for example: accounts; a business plan; information about ownership of intellectual or industrial property; or expert opinions including valuations or auditors' reports;
- (iv) prospective investors should be aware that no established market exists for the trading of any securities that may be offered; and
- (v) this publication/advertisement is subject to Class Order [02/273] issued under the Corporations Act 2001 (Cth).

**ASIC CLASS ORDER 02/273 PROMINENT STATEMENTS**

The information contained in the Publication about the proposed business opportunity and the securities or scheme interests is not intended to be the only information on which the investment decision is made and is not a substitute for a disclosure document, Product Disclosure Statement or any other notice that may be required under the Act, as that Act may apply to the investment. Detailed information may be needed to make an investment decision, for example: financial statements; a business plan; information about ownership of intellectual or industrial property; or expert opinions including valuations or auditors' reports.

A prospective investor is strongly advised to take appropriate professional advice before accepting an offer for issue or sale of any securities or scheme interests.